Savings from sub-groups?: Policy guidance and Alzheimer\u27s disease treatments by McNamee P et al.
Newcastle University e-prints  
Date deposited:  24th January 2011 
Version of file:  Author final 
Peer Review Status: Peer-reviewed 
Citation for published item: 
McNamee P, Vanoli A, Hutchings D, Mckeith I, Bond J. Savings from sub-groups?: Policy guidance and 
Alzheimer's disease treatments. Journal of Nutrition, Health and Aging 2010, 14(8), 664-668. 
Further information on publisher website: 
http://www.springerlink.com/ 
Publisher’s copyright statement: 
The final publication of this article is available at www.springerlink.com at the following link: 
http://dx.doi.org/10.1007/s12603-010-0313-5 
 Always use the definitive version when citing.   
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in Newcastle E-prints 
• The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU.  Tel. 0191 222 6000 
 1
Savings from sub-groups?: policy guidance and Alzheimer’s Disease treatments 
 
Paul McNamee1, Alessandra Vanoli2, Deborah Hutchings3, Ian McKeith4, John 
Bond5 
 
1. Senior Research Fellow, Health Economics Research Unit, Institute of Applied 
Health Sciences, University of Aberdeen, AB25 2ZD. 
 
2. Senior Research Associate, School of Population and Health Sciences, Centre for 
Health Services Research, University of Newcastle, NE2 4AA.. 
 
3. Research Associate, School of Population and Health Sciences, Centre for Health 
Services Research, University of Newcastle, NE2 4AA.. 
 
4. Professor of Old Age Psychiatry, Institute for Ageing and Health, Wolfson 
Research Centre, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE. 
 
5. Professor of Social Gerontology and Health Services Research, School of 
Population and Health Sciences, Centre for Health Services Research, University 
of Newcastle, NE2 4AA. 
 
Author for correspondence: 
 
Paul McNamee, Senior Research Fellow, Health Economics Research Unit, Institute of 
Applied Health Sciences, University of Aberdeen, AB25 2ZD. 
 
Telephone: 01224 551893 
Fax: 01224 550926 
Email: p.mcnamee@abdn.ac.uk 
 
Conflict of interest 
 
J Bond has acted as a consultant to Pfizer and BioScience Communications for 
European Dementia Forum to raise awareness of dementia in Europe during 2004-5. 
All other authors declare that they have no conflict of interest. 
 2
 
Acknowledgements 
Financial support for this study was provided in part by a grant from the Wellcome 
Trust, grant number GR065129. We also acknowledge the financial support of the 
Institute of Applied Health Sciences, University of Aberdeen, and the Chief Scientist’s 
Office (CSO) of the Scottish Government Health Directorates.  The funding bodies and 
sponsors had no role in study design, data collection, analysis or interpretation of the 
data, in the writing of the paper or in the decision to submit the paper for publication. 
The views expressed in the paper are those of the authors alone and do not necessarily 
represent those of the CSO or any other funding body. 
 
 3
 
Abstract 
 
Background 
A range of new therapeutic agents are now available for the management of Alzheimer’s 
disease.  With limited resources available however, policy-makers and other health care 
professionals have to prioritise and judge competing treatments on criteria such as the 
magnitude of clinical effectiveness and cost-effectiveness.  Policy guidance that restricts 
treatments to defined patient sub-groups can improve the cost-effectiveness of 
treatments, and can help limit rises in health care expenditures.  Budget impact models 
that estimate the amount of additional costs and potential savings are being increasingly 
used by policy-makers.  However, the amount of savings estimated in such models 
depends on the effectiveness of treatment in changing morbidity, and the association 
between morbidity and costs.   
 
Aim 
To examine the magnitude of cost savings arising from provision of treatment to 
different patient sub-groups, using policy guidance decisions made by the National 
Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies 
in Alzheimer’s Disease (AD) in the United Kingdom National Health Service (NHS).  
 
Method 
Cohort simulation modelling. 
 
Results 
Policy guidance decisions that restricted treatment to smaller patient sub-groups were 
associated with lower overall care costs, but did not reduce drug costs. 
 
Conclusions 
Given increasing recognition by health policy-makers of the importance of affordability 
of new treatments, greater attention should be paid to measurement of cost impacts by 
sub-groups within health economic modelling.   
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Introduction 
 
Currently there is no cure for dementia, but since 1997 treatments have been available 
for people in the mild to moderate stages of Alzheimer’s disease (1).  These treatments, 
which belong to the cholinesterase inhibitor class of drugs, have been shown to provide 
some improvement or maintenance of cognitive functioning for a limited period in some 
eligible patients.  Results from clinical trials have found that the treatments, when 
effective, can postpone the onset of more severe cognitive decline for 6 to 12 months (2-
4), although it is not clear whether they affect the progression of the disease in the longer 
term (5).  There is some evidence that they may also help maintain ability to perform 
activities of daily living (6,7), alleviate some behavioural symptoms (8) and improve 
mood (9).  However, there is inconclusive evidence regarding improvement in overall 
quality of life (3).  Regarding costs and cost-effectiveness, a number of studies have been 
conducted assessing different cholinesterase inhibitor agents (10-17).  In a review of 
these studies by Jonsson (18), it was noted that the donepezil studies broadly indicated 
that treatment costs would be likely balanced by cost savings, whilst for galantamine, 
additional costs would likely be accompanied by some modest improvement in quality of 
life.  More recently, an estimate produced for the UK suggested that cholinesterase 
inhibitor treatment would be unlikely to be regarded as a cost-effectiveness use of 
resources (19).  Consensus therefore is lacking on the relative cost-effectiveness of 
treatment, mostly due to difficulties in modelling changes in disease progression and 
subsequent quality of life, and estimates of cost-effectiveness continue to be regarded 
with some caution.  
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The National Institute for Health and Clinical Excellence (NICE) was established in the 
United Kingdom (UK) to decide whether selected health technologies, such as the 
cholinesterase inhibitor class of drugs described above, should be made available for use 
by the National Health Service (NHS).  NICE guidance is intended to replace local 
decisions on use of new health technologies and thereby promote equal access to 
treatments for patients with similar levels of health needs.  Similar bodies that exist 
elsewhere include the Pharmaceutical Benefits Advisory Committee in Australia and the 
Common Drug Review in Canada.  Policy guidance from such bodies usually takes the 
form of a single yes (no) decision for all patients who could be offered the health 
technology, based on whether the mean Incremental Cost Effectiveness Ratio (ICER) is 
below (above) a threshold value per Quality Adjusted Life Year (QALY).  This decision 
rule however pays no attention to the size or composition of potential beneficiaries, or to 
the costs or “budget impact” associated with provision of the technology (20). 
 
An example of a recent departure from this approach however relates to cholinesterase 
inhibitor therapies for Alzheimer’s Disease (AD).  The recommendation is that treatment 
should be made available only to a sub-group with moderate disease, rather than all or no 
patients (21,22).  Specifically, individuals with Mini-Mental State Examination (MMSE) 
between 10 and 20 are eligible to receive therapy following a clinical diagnosis in a 
specialist clinic.  Furthermore, they should normally only continue to receive therapy 
whilst the score remains within these levels and while global, functional and behaviour 
conditions remain at a level commensurate with therapy continuing to have a worthwhile 
effect.  The previous recommendation was that treatment could be provided to patients 
with mild or moderate disease, the latter defined as MMSE greater than 12 (23).  
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The change in guidance was driven by differences in the cost-effectiveness for different 
patient sub-groups. Although affordability concerns are not formally considered within 
appraisals of new technologies by national bodies (24-26), policy guidance based on sub-
groups may have an important positive spin-off, through generation of expenditure 
savings.  Such savings may be critical for health planners, who are required to identify 
areas of disinvestment in order to fund new treatments.  We may anticipate greater focus 
in future years on guidance that places restricted access on new treatments, as the current 
economic climate puts greater pressure on public budgets. 
 
The extent of savings however depends on the association between morbidity and costs, 
and the effectiveness of therapy on disease progression.  In the case of Alzheimer’s 
Disease treatments, although there are more patients with mild or moderate disease 
relative to moderate disease, treatment of patients with mild disease may lead to 
substantial delay of disease progression, and avoidance of costs associated with moderate 
disease may outweigh any additional drug treatment costs.  Thus, it is possible that 
treatment of the larger group, comprising those with mild or moderate disease, may be 
less expensive than treatment of the smaller group with moderate disease only.  
 
There has been little previous research that has estimated the cost implications associated 
with sub-group guidance relative to single yes/no guidance.  The objective of this paper 
therefore was to quantify the magnitude of incremental costs (i.e. the difference in health 
and social care costs with and without treatment) associated with sub-group guidance, 
using as a case study NICE guidance on cholinesterase inhibitor therapy for AD to the 
UK health and social care system.      
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Methods 
The cost impact of different policy guidance was estimated using cohort simulation 
modelling.  Figure 1 shows the model structure.  Age and gender-specific sub-cohorts 
start with an initial mean MMSE level and an accompanying distribution.  There is a 
probability of survival, death and MMSE decline each year, leading to a smaller number 
of individuals eligible for therapy under NICE guidance each year.  This cycle is then 
repeated a further nine times.  The cohort comprises the total population with AD in 
England and Wales, based on the most recent population estimates (27) and AD 
prevalence rates (28).  Treatment costs (price of cholinesterase inhibitor medication) and 
total AD care costs (cholinesterase inhibitors and other long-term care resources such as 
nursing home care) were calculated over ten years using three different policy models.  
First, a “NICE Guidelines-Mild and Moderate” (NG-MM) model, where only those with 
a level of MMSE greater than 12 commenced therapy and were withdrawn from therapy 
when MMSE was no longer greater than 12, a “NICE Guidelines-Moderate” (NG-M) 
model, where individuals with MMSE between 10 and 20 were treated, and were 
withdrawn from therapy when MMSE fell below 10, and finally, a “NICE Guidelines-
All” (NG-ALL), where all individuals with AD were treated, irrespective of MMSE. 
 
All three models relied on the same data sources.  The clinical effects of treatment on 
cognition and survival were modelled using observational cohort data (29) and natural 
history studies (30,31).  Summary information from a systematic review of placebo-
controlled trials of donepezil (3) was used to validate the estimates of effectiveness of 
therapy on cognition.  AD care costs were modelled as a function of age, gender, Mini-
Mental State Examination (MMSE) score and Activities of Daily Living (ADL) score, in 
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a generalized linear model framework (32,33).  Resource use and cost data were obtained 
from a previous UK observational multi-centre study that included older people with 
dementia (34).  
 
The sensitivity of the results to different model assumptions was explored using 
probabilistic sensitivity analysis.  This involved taking repeated random draws from 
specific distributions of stochastic parameters (MMSE and ADL baseline values, MMSE 
change per year, proportions eligible to receive therapy, survival, regression coefficients).  
Ninety-five percent credible intervals were computed by taking the rank ordered 25th and 
975th estimates of costs from the 1,000 repeated random draws.  All costs are reported in 
2002/3 prices.  Assumptions for model parameters are outlined in Tables 1 and 2.  
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Results 
Table 3 shows that for the NG-MM model, mean incremental AD care costs were £116 
million over 10 years, or £603 per patient over 10 years (£1=US$1.53=€1.31, at 2008 
purchasing power parities).  Costs of cholinesterase inhibitor treatment amounted to 
£237 million (£1231 per patient over 10 years).  For the NG-M model, mean incremental 
AD care costs were £100 million, or £582 per patient over 10 years.  Treatment costs 
totalled £245 million (£1421 per patient over 10 years).  For the NG-ALL model, mean 
incremental AD care costs were £607 million over 10 years.  On a per patient basis, this 
equated to £1977.  Treatment costs were £865 million (£2816 per patient over 10 years). 
 
Table 3 also indicates that the findings from the probabilistic sensitivity analysis reveal 
that the results were robust to changes in model assumptions; in particular credible 
intervals were always higher than zero, showing that treatment is unlikely to produce 
savings large enough to offset the immediate direct costs of treatment.  Out of the 1,000 
repetitions, there was a 0.1% probability of cost savings of £53 per patient per year in the 
NG-MM model, and a 0.6% probability of cost savings ranging of £1-£165 per patient 
per year in the NG-M model.  There was a zero probability of cost savings in the NG-
ALL model, where the lowest incremental cost per patient per year was £1,041.      
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Discussion 
The analyses in this paper suggest that provision of cholinesterase inhibitors for the 
management of AD imposes additional costs to the health and social care system.  
Secondly, relative to providing treatment for all patients with AD, restriction of therapy 
to sub-groups is associated with significant cost savings.  Provision of therapy to the 
patient sub-group with mild or moderate disease instead of to all patients was estimated 
to provide drug acquisition cost savings of £628 million.  However, further restriction to 
those with moderate disease produced no additional savings in the drugs budget.  On the 
contrary, drug costs were found to be larger amongst the smaller sub-group with 
moderate disease.  This result arose as, over time, more patients enter a state of moderate 
disease and exit from the group with mild disease, and, in addition, a lower cut-off is 
used to define moderate disease under the most recent guidance (MMSE=>10 instead of 
MMSE>12).  In terms of overall care costs however, the moderate sub-group was less 
expensive than the mild to moderate group by approximately £16 million over 10 years.   
 
This paper, to the best of our knowledge, is the first to quantify the costs and cost 
savings associated with different types of guidance decisions using currently 
recommended methods for estimation of budget impact (24).  Thus, it is difficult to 
compare the results with other studies.  Previously NICE estimated that treatment for 
mild and moderate patients would cost £42 million per year in drug expenditure (23).  
No comparable information is available however on the cost implications associated with 
therapy for the moderate disease only sub-group.  Further, there are no estimates on the 
impact on other resources, such as long-term care in residential or nursing homes, nor 
quantification of the uncertainty surrounding the estimates.   
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In generating cost estimates using modelling, it is important to assess model validity.  A 
recent study calculates mean annual health and social care costs per person (2005/6 
prices) of £7,400 for mild and £8,700 for moderate dementia respectively (35).  Within 
our model, mean annual costs were £8000, providing evidence of convergent validity.  A 
further consideration is the credibility of the values generated; here a one point reduction 
in MMSE was associated with a mean cost saving of £414 per person per year (pp/py).  
This implies a saving of approximately 1 week in long-stay residential care, consistent 
with the estimate of 2-5 days less institutional care pp/py for a 0.8 MMSE reduction 
demonstrated in the AD2000 trial (36).  It should be noted however that informal care 
costs were not estimated here, as these are not included in NICE budget impact values.   
 
A potential limitation of the study relates to the integration of data from various sources 
to arrive at an estimate of costs and cost savings.  In particular, disease progression with 
and without treatment was modelled using data from two different patient groups in the 
United States recruited from secondary care (29,30), and applied to cost data generated 
from a community based sample in the United Kingdom (34).  In the disease progression 
with treatment study (29), diagnosis was made according to neurological examination and 
neuropsychological assessment.  Respondents had a mean age of 73 years, 66% of the 
sample was female, and mean baseline MMSE was 19.  In the natural history without 
treatment study (30), diagnosis of probable AD without stroke was based on neurological 
examination, brain scan, neuropsychological assessment and laboratory analysis.  
Respondents had a mean age of 75 years, 71% of the sample was female, and mean 
baseline MMSE was 19.5.  In the UK study, data were drawn from those resident in the 
community at baseline with a score of three or more on the organic section of the 
Automated Geriatric Examination Computer Assisted Taxonomy (`AGECAT'), which is 
approximately equivalent to moderate (or more) clinical dementia.  Respondents had a 
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mean age of 81 years, 63% of the sample was female, baseline MMSE was 17 and mean 
education an MMSE.  Thus, aside from the somewhat higher age and slightly lower 
MMSE in the third study, the samples appear to be drawn from reasonably similar 
patient groups.    Further, all three studies used data from non-selected cohorts, so the 
risk of problems related to selection bias should be minimised.  Finally, the age-specific 
MMSE reductions used in the model approximate the mean value of 1.8 (95% 
confidence interval 0.5-3.1) estimated from a systematic review of randomised controlled 
trials (3), suggesting that the data from the non-selected cohorts is not adversely affected 
by attrition bias from patients being lost to follow-up.    
 
Given increasing recognition by policy-makers of the importance of identifying cost-
effective treatments that are financially sustainable, greater attention should be paid to 
measurement of affordability in health care modelling.  The work reported here describes 
and applies a technique that can be used to assess the affordability of different forms of 
policy guidance.  Further modelling studies that consider the cost as well as the health 
impact associated with sub-group policy guidance for other treatments and diseases 
would be welcome.  
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Table 1. Model Assumptions and Parameters 
Parameter Value/assumption Data Source 
 
Population of England and 
Wales aged 65 years or over 
in mid 2002 
 
 
8,385,800 
 
National Statistics (27). 
Prevalence of AD 50% of age & sex specific 
rates for dementia 
MRC CFAS (28). 
Cohort size 192,000 (NG-MM) 
172,000 (NG-M) 
307,000 (NG-ALL) 
National Statistics (27),  
MRC CFAS (28). 
 
Cohort distribution by 
baseline MMSE  
 
Age & sex specific values; 
mean score ranges from a 
minimum of 12.7 to a 
maximum of 18.6 
 
McNamee et al (34). 
 
Cohort ADL distribution  
 
Age & sex specific values’ 
mean score ranges from a 
minimum of 6.5 to a 
maximum of 13.8 
 
McNamee et al (34). 
 
Cohort distribution by 
baseline costs per person 
per year 
 
Age & sex specific values 
from a minimum of £1584 
to a maximum of £14,457 
 
McNamee et al (34). 
 
MMSE reduction per year 
without therapy 
 
Age specific values from a 
minimum of 2 to a 
maximum of 3 
 
Mungas et al (30). 
 
MMSE reduction per year 
with therapy 
 
Age specific values from a 
minimum of 1.2 to a 
maximum of 1.8 
 
Lopez et al (29). 
 
Therapy costs per person 
per year 
 
£891 
 
BMA RPS British National 
Formulary (37). 
 
Cost savings per person per 
year per MMSE point 
reduction  
 
£414 
 
Regression estimates. 
 
Discount rate 
 
3.5% 
 
HM Treasury Green Book 
(38). 
 
Five year survival 
probability  
 
Age & sex specific values 
from a minimum of 0.18 to 
0.69 
 
Neale et al (31). 
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Table 2. Age and sex specific model parameters 
 
Age 
(years) 
Prevalence AD 
population 
Costs 
per 
year 
(£) 
Survival 
5 yrs 
MMSE 
baseline 
ADL 
baseline 
MMSE 
reduction 
per year – 
no 
treatment 
(treatment) 
MEN        
65-69 0.7 7807 5287 0.605 16.9 12.3 3 (1.8) 
70-74 1.5 14726 6664 0.605 17.8 11.6 3 (1.8) 
75-79 2.8 20451 7993 0.395 18.1 11.4 2.5 (1.5) 
80-84 5.1 23959 10738 0.395 16.7 10.0 2.5 (1.5) 
>=85 9.8 27930 14457 0.18 14.5 7.2 2 (1.2) 
        
WOMEN        
65-69 0.7 8992 1584 0.69 17.7 13.8 3 (1.8) 
70-74 1.1 12375 2603 0.69 18.6 13.8 3 (1.8) 
75-79 3.5 35443 6986 0.51 16 10.1 2.5 (1.5) 
80-84 7.0 55363 10522 0.51 12.7 8.6 2.5 (1.5) 
>=85 13.8 100031 12921 0.35 12.8 6.6 2 (1.2) 
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Table 3. Mean incremental AD care and drug costs per cohort and per patient 
over 10 years 
 
Policy 
Guidance 
Incremental AD 
care costs cohort 
£m (95% credible 
interval) 
Incremental 
AD care costs   
patient £  
(95% credible 
interval) 
Drug acquisition 
costs cohort £m 
(95% credible 
interval) 
Drug acquisition 
costs patient  £ 
(95% credible 
interval) 
NG-MM  116 (42-187) 603 (218-971) 237 (221-254) 1231 (1146-
1318) 
NG-M  100 (20-189) 582 (102-983) 245 (227-264) 1421 (1315-
1531) 
NG-ALL  607 (461-759) 1977 (1502-
2473) 
865 (823-906) 2816 (2680-
2952) 
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Figure 1.  Outline of Model Structure 
 
 
 
Note: The figures in parentheses show the values for males aged 65-69 years, without 
therapy, under the NG-MM model (eligible if MMSE is greater than 12).  Different 
values apply to other sub-cohorts, please see Table 2.  
 
 
 
 
 
 
 
 
MMSE t0 
(mean=17) 
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(p=0.33) 
Eligible 
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MMSE t1 
(mean=14) 
 
Die (p=0.10) 
 
Survive (p=0.90) 
